Cagrilintide 5mg + Semaglutide 5mg

Cagrilintide 5mg + Semaglutide 5mg This product combines two advanced research peptides, Cagrilintide and Semaglutide, both of which are under investigation for their roles in metabolic regulation, appetite signaling, and energy balance. • Cagrilintide is an amylin analogue designed to activate amylin receptors involved in appetite suppression, satiety signaling, and weight regulation. • Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, widely studied for its ability to influence insulin secretion, glucose metabolism, and satiety. When studied together, these peptides allow researchers to explore synergistic mechanisms in energy homeostasis, appetite control, and glucose balance. This combination is of high interest in metabolic and obesity-related research fields. Potential Research Benefits: • Investigation of appetite regulation pathways • Study of GLP-1 and amylin receptor interactions • Research into glucose metabolism and insulin signaling • Exploration of combination therapies for metabolic disorders Product Details: • Contents: 5mg Cagrilintide + 5mg Semaglutide per vial (10mg total peptide blend) • Purity: ≥98% (HPLC tested) • Form: Lyophilized powder • Appearance: White/off-white crystalline powder • Storage: Store lyophilized at –20°C; after reconstitution keep at 2–8°C • Usage: For laboratory and scientific research only. Not for human consumption. Key Features: • Dual-action research peptide blend • High-purity, HPLC-tested for reliability • Sterile, sealed vial for long-term stability • Developed for advanced studies in metabolism and energy balance